Storys zum Thema Medizinische Behandlung

STADA Arzneimittel AG

2

Press Release: STADA’s Strong Growth Journey Continues in 2025

STADA Arzneimittel AG

Press Release: STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi

STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi - European Commission grants approval for Gotenfia®, a golimumab biosimilar to Simponi® that was developed by Bio-Thera and will be marketed by STADA ...

STADA Arzneimittel AG

Press Release: Golimumab biosimilar Gotenfia from STADA and Bio-Thera receives positive CHMP opinion

Golimumab biosimilar Gotenfia from STADA and Bio-Thera receives positive CHMP opinion - Positive opinion from European Medicines Agency supports approval for golimumab biosimilar Gotenfia® developed by Bio-Thera and to be marketed by STADA - ...

STADA Arzneimittel AG

Press Release: STADA obtains approvals to bring denosumab biosimilars in bone-health and oncology to patients in Europe

STADA obtains approvals to bring denosumab biosimilars in bone-health and oncology to patients in Europe - European Commission approves STADA’s Kefdensis® and Zvogra® denosumab biosimilars for all indications of reference medicines Prolia® and ...

STADA Arzneimittel AG

Press release: Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. Press release ...

STADA Arzneimittel AG

3

Press Release STADA’s growth journey continues in 2024 - Significant increase in sales and profits - Growing ahead of the market